Milestone Pharmaceuticals Inc. Logo

Milestone Pharmaceuticals Inc.

Developing a self-administered nasal spray for at-home treatment of acute cardiac events.

MIST | US

Overview

Corporate Details

ISIN(s):
USU6005B1045 (+1 more)
LEI:
549300P43IPGW3Q3Y026
Country:
United States of America
Address:
1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, 07039 MONTREAL
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Milestone Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics for episodic cardiovascular conditions. The company's lead investigational product is etripamil, a proprietary, novel calcium channel blocker delivered as a self-administered nasal spray. This therapy is designed for the rapid termination of paroxysmal supraventricular tachycardia (PSVT) episodes in an at-home setting, addressing a significant unmet need for treatment outside of the emergency department. Milestone is also exploring etripamil's potential for other conditions, such as atrial fibrillation with rapid ventricular rate (AFib-RVR), to provide patients with control over acute cardiac events.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Milestone Pharmaceuticals Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Milestone Pharmaceuticals Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Milestone Pharmaceuticals Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

CELL BIOTECH CO ., LTD Logo
A global biotech firm offering probiotic raw materials, OEM/ODM services, and consumer brands.
South Korea
049960
Celldex Therapeutics, Inc. Logo
Develops antibody-based therapies for severe inflammatory, allergic, and autoimmune diseases.
United States of America
CLDX
Cellectar Biosciences, Inc. Logo
Late-stage biopharma developing targeted cancer therapies with a proprietary PDC delivery platform.
United States of America
CLRB
Cellectis Logo
Develops 'off-the-shelf' CAR T-cell cancer immunotherapies using TALEN® gene-editing.
France
ALCLS
Cellid Co., Ltd. Logo
Biotech firm developing proprietary vaccine platforms for cancer and infectious diseases.
South Korea
299660
Cellromax Science Co., Ltd. Logo
Develops health foods, derma-cosmetics, and OTC drugs for pharmacies and online channels.
South Korea
471820
CellSeed Inc. Logo
Develops cell sheet products, culture equipment, and offers contract manufacturing services.
Japan
7776
CellSource Co.,Ltd. Logo
Processes patient-derived stem cells and PRP for regenerative therapies at medical facilities.
Japan
4880
Celltrion, Inc. Logo
A biopharma pioneer developing biosimilars and novel drugs for immunology and oncology.
South Korea
068270
Celon Pharma S.A. Logo
Researches, develops, and markets innovative drugs for oncology and neurology.
Poland
CLN

Talk to a Data Expert

Have a question? We'll get back to you promptly.